Federal Register / Vol. 62, No. 56 / Monday, March 24, 1997 / Rules and Regulations 13821

1The Filer Manual originally was adopted on

April 1, 1993, and became effective on April 26,

1993. Release No. 33–6986 (April 1, 1993) [58 FR

18638]. The most recent update to the Filer Manual

was adopted in Release No. 33–7394 (February 21,

1997) [61 FR 8877], and became effective on March

10, 1997.

2See Release Nos. 33–6977 (February 23, 1993)

[58 FR 14628], IC–19284 (February 23, 1993) [58 FR

14848], 35–25746 (February 23, 1993) [58 FR

14999], and 33–6980 (February 23, 1993 [58 FR

15009] for a comprehensive treatment of the rules

adopted by the Commission governing mandated

electronic filing. See also Release No. 33–7122

(December 19, 1994) [59 FR 67752], in which the

Commission made the EDGAR rules final and

applicable to all domestic registrants and adopted

minor amendments to the EDGAR rules; Release

No. 33–7394, in which the Commission adopted the

most recent update to the Filer Manual; and Release

No. 33–7369 (December 5, 1996) [61 FR 65440], in

which the Commission proposed additional minor

technical amendments to the EDGAR rules.

3 17 CFR 274.21 (certificate of accounting of

securities and similar investments in the custody of

management investment companies filed pursuant

to Rule 17f–1).

4 17 CFR 274.220 (certificate of accounting of

securities and similar investments in the custody of

management investment companies filed pursuant

to Rule 7f–2).

5 17 CFR 240.23c–2(b) (notice by closed-end

investment companies of intention to call or redeem

their own securities).

6 17 CFR 274.221 (notification of periodic

repurchase offer).

7 17 CFR 240.23c–3. Submission type ‘‘N–23C3A’’

is to be used for filings made pursuant to Rule 23c–

3(a) only; ‘‘N–23C3B,’’ Rule 23c–3(b) only; and ‘‘N–

23C3C,’’ Rule 23c–3(a) and (b).

8 17 CFR 230.462(b).

9 15 U.S.C. 77a et seq. The new submission types

are: S–4MEF (for use in connection with

registration statements filed on Form S–4 [17 CFR

239.25]) and F–4MEF (for use in connection with

registration statements on Form F–4 [17 CFR

239.34]). All other submission types used for Rule

462(b) filings were added to the EDGAR system in

November 1995. See Release No. 33–7241

(November 13, 1995) [60 FR 57682]

through the Electronic Data Gathering,

Analysis, and Retrieval (‘‘EDGAR’’)

system.1 Compliance with the

provisions of the Filer Manual is

required in order to assure the timely

acceptance and processing of filings

made in electronic format. Filers should

consult the Filer Manual in conjunction

with the Commission’s rules governing

mandated electronic filing when

preparing documents for electronic

submission.2

In this update, several submission

types have been added to accommodate

electronic submission of certain

investment company filings.

Specifically, new EDGAR submission

types ‘‘40–17F1’’ and ‘‘40–17F2’’ have

been added to accommodate the filing of

Forms N–17F–1 3 and N–17F–2; 4

submission type ‘‘N–23C–2,’’ to

accommodate filings under Rule 23c–

2(b); 5 and submission types ‘‘N–

23C3A,’’ ‘‘N–23C3B,’’ and ‘‘N–23C3C,’’

to accommodate the filing of Form

N–23C–3,6 pursuant to Rule 23c–3.7

With respect to documents subject to

review by the Division of Corporation

Finance, two additional submission

types have been added to accommodate

more completely the electronic

submission of filings made pursuant to

Rule 462(b) 8 under the Securities Act of

1933.9

Rule 301 of Regulation S–T was

amended to provide for the

incorporation by reference of the Filer

Manual into the Code of Federal

Regulations, which incorporation by

reference was approved by the Director

of the Federal Register in accordance

with 5 U.S.C. 552(a) and 1 CFR Part 51.

The effective date of the amendment to

Rule 301 will remain March 10, 1997. A

minor correction is being made to

conform to the Office of Federal

Register’s requirements for

incorporation by reference.

Technical issues surfaced on the

afternoon of March 7, 1997 that

prevented system implementation on

March 10, 1997. The Commission,

therefore, is postponing the

implementation of the Manual from

March 10, 1997 to March 24, 1997.

Need for Correction

As published, the final regulations

contain an error which may prove to be

misleading and is in need of

clarification.

Correction of Publication

Accordingly, the publication on

February 27, 1997 of the final

regulations, which were the subject of

FR Doc. 97–4797, is corrected as

follows:

§ 232.301 [Corrected]

On page 8876, second column, in

§ 232.301, last line, add a sentence to

the end of the section to read as follows:

* * * Copies may be inspected at the

Office of the Federal Register, Suite 700,

800 North Capitol Street, N.W.,

Washington, D.C.

Dated: March 19, 1997.

By the Commission.

Jonathan G. Katz,

Secretary.

[FR Doc. 97–7340 Filed 3–21–97; 8:45 am]

BILLING CODE 8010–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

21 CFR Part 5

Delegations of Authority and

Organization

AGENCY: Food and Drug Administration,

HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug

Administration (FDA) is amending the

regulations for delegations of authority

to set forth the current organizational

structure of the agency as well as the

current addresses for headquarters and

field offices. The agency is also

redesignating certain sections of the

regulations to allow for expansion in the

delegation of authority section. This

action is necessary to ensure the

continued accuracy of the regulations.

EFFECTIVE DATE: March 24, 1997.

FOR FURTHER INFORMATION CONTACT:

L’Tonya J. Barnes, Division of

Management Systems and Policy (HFA–

340), Food and Drug Administration,

5600 Fishers Lane, Rockville, MD

20857, 301–827–4807.

SUPPLEMENTARY INFORMATION: The

regulations are being amended in

subpart C of part 5 (21 CFR part 5) to

reflect the central organization of the

agency and to provide current addresses

for headquarters and field offices. The

regulations are also being amended by

redesignating §§ 5.100, 5.105, 5.110, and

5.115 as §§ 5.200, 5.205, 5.210, and

5.215, respectively, to permit the

expansion of subpart B to allow for

added delegations.

Notice and comment on these

amendments are not necessary under

the Administrative Procedure Act

because this is a rule of agency

organization (5 U.S.C. 553(b)).

List of Subjects in 21 CFR Part 5

Authority delegations (Government

agencies), Imports, Organization and

functions (Government agencies).

Therefore, under the Federal Food,

Drug, and Cosmetic Act and under

authority delegated to the Commissioner

of Food and Drugs, 21 CFR part 5 is

amended as follows:

PART 5—DELEGATIONS OF

AUTHORITY AND ORGANIZATION

1. The authority citation for 21 CFR

part 5 continues to read as follows:

Authority: 5 U.S.C. 504, 552, App. 2; 7

U.S.C. 138a, 2271; 15 U.S.C. 638, 1261–1282,

3701–3711a; secs. 2–12 of the Fair Packaging
13822 Federal Register / Vol. 62, No. 56 / Monday, March 24, 1997 / Rules and Regulations

1Mailing address: 5600 Fishers Lane, Rockville,

MD 20857.

2Mailing address: Jefferson, AR 72079–9502.

3Mailing address: 5600 Fishers Lane, Rockville,

MD 20857.

4Mailing address: 7500 Standish Pl., rm. 250N,

Rockville, MD 20855.

5Mailing address: 850 Third Ave., Brooklyn, NY

11232.

6Mailing address: 900 U. S. Customhouse,

Second and Chestnut Sts., rm. 900, Philadelphia,

PA 19106.

7Mailing address: 60 Eighth St. NE., Atlanta, GA

30309.

8Mailing address: 20 North Michigan Ave.,

Chicago, IL 60606.

9Mailing address: 7920 Elmbrook Dr., Dallas, TX

75247.

10Mailing address: 13301 Clay St., Oakland, CA

94512.

11Mailing address: 1401 Rockville Pike, suite

200N, Rockville, MD 20852–1448.

12Mailing address: 1451 Rockville Pike, rm. 6027,

Rockville, MD 20850.

and Labeling Act (15 U.S.C. 1451–1461); 21

U.S.C. 41–50, 61–63, 141–149, 467f, 679(b),

801–886, 1031–1309; secs. 201–903 of the

Federal Food, Drug, and Cosmetic Act (21

U.S.C. 321–394); 35 U.S.C. 156; secs. 301,

302, 303, 307, 310, 311, 351, 352, 361, 362,

1701–1706, 2101 of the Public Health Service

Act (42 U.S.C. 241, 242, 242a, 242l, 242n,

243, 262, 263, 264, 265, 300u–300u–5,

300aa–1); 42 U.S.C. 1395y, 3246b, 4332,

4831(a), 10007–10008; E.O. 11490, 11921,

and 12591.

§ 5.100 [Redesignated as § 5.200]

2. Section 5.100 is redesignated as

§ 5.200 and revised to read as follows:

§ 5.200 Headquarters.

The central organization of the Food

and Drug Administration consists of the

following:

Office of the Commissioner.1

Office of the Administrative Law Judge.

Office of Executive Secretariat.

Office of Equal Employment and Civil

Rights.

Office of the Chief Counsel.

Office of Internal Affairs.

Office of External Affairs.

Industry and Small Business Liaison

Staff.

Office of Special Health Issues.

Office of Consumer Affairs.

Office of Health Affairs.

Office of Legislative Affairs.

Office of Public Affairs.

Office of Women’s Health.

Office of International Affairs.

Office of Management and Systems.

Office of Planning and Evaluation.

Office of Human Resources and

Management Services.

Office of Facilities, Acquisitions, and

Central Services.

Office of Information Resources

Management.

Office of Financial Management.

Office of Policy.

Regulations Policy and Management

Staff.

Policy Development and Coordination

Staff.

Policy Research Staff.

International Policy Staff.

Office of Operations.

Office of Science.

Office of Orphan Products

Development.

National Center for Toxicological

Research.2

Office of the Center Director

Environmental Health and Program

Assurance Staff.

Equal Employment Opportunity Staff.

Scientific Coordination Staff.

Technology Advancement Staff.

Office of Planning and Resource

Management

Planning Staff.

Financial Management Staff.

Evaluation Staff.

Office of Research

Research Coordination Staff.

Biomarkers Laboratory Staff.

Division of Reproductive and

Developmental Toxicology.

Division of Genetic Toxicology.

Division of Biochemical Toxicology.

Division of Nutritional Toxicology.

Division of Biometry and Risk

Assessment.

Division of Chemistry.

Division of Microbiology.

Division of Neurotoxicology.

Office of Research Support

Veterinary Services Staff.

Information Technology Staff.

Division of Administrative Services.

Division of Facilities Engineering and

Maintenance.

Office of Regulatory Affairs.3

Office of the Associate Commissioner

Contaminants Policy Coordination Staff.

Equal Employment Opportunity Staff.

Strategic Initiatives Staff.

Office of Resource Management

Division of Planning, Evaluation, and

Management.

Division of Information Systems.

Division of Human Resource

Development.

Division of Management Operations.

Office of Enforcement

Medical Products Quality Assurance

Staff.

Division of Compliance Management

and Operations.

Division of Compliance Policy.

Office of Regional Operations

Division of Federal-State Relations.

Division of Field Science.

Division of Emergency and

Investigational Operations.

Division of Import Operations and

Policy.

Office of Criminal Investigations4

Northeast Regional Office.5

Mid-Atlantic Regional Office.6

Southeast Regional Office.7

Midwest Regional Office.8

Southwest Regional Office.9

Pacific Area Office.10

Center for Biologics Evaluation and

Research.11

Office of the Center Director

Equal Employment Opportunity Staff.

Scientific Advisors and Consultants

Staff.

Quality Assurance Staff.

Congressional and Public Affairs Staff.

Office of Communication, Training and

Manufacturers Assistance

Division of Congressional and Public

Affairs.

Division of Manufacturers Assistance

and Training.

Office of Management

Division of Management Services.

Division of Applied Information

Technology.

Division of Planning, Evaluation, and

Budget.

Office of Compliance

Division of Case Management.

Division of Regulations and Policy.

Division of Inspections and

Surveillance.

Office of Therapeutics Research and

Review

Division of Cytokine Biology.

Division of Cellular and Gene

Therapies.

Division of Hematologic Products.

Division of Monoclonal Antibodies.

Division of Clinical Trial Design and

Analysis.

Division of Application Review and

Policy.

Office of Vaccines Research and Review

Division of Allergenic Products and

Parasitology.

Division of Bacterial Products.

Division of Viral Products.

Division of Vaccines and Related

Products Applications.

Office of Establishment Licensing and

Product Surveillance

Division of Product Quality Control.

Division of Veterinary Services.

Division of Biostatistics and

Epidemiology.

Division of Establishment Licensing.

Division of Congressional Public Affairs.

Office of Blood Research and Review

Division of Blood Applications.

Division of Transfusion Transmitted

Diseases.

Division of Hematology.

Division of Blood Establishment &

Products.

Center for Drug Evaluation and

Research.12

Office of the Center Director

Advisors and Consultants Staff.

Pilot Drug Evaluation Staff.

Executive Operations Staff.
Federal Register / Vol. 62, No. 56 / Monday, March 24, 1997 / Rules and Regulations 13823

13Mailing address: 7500 Standish Pl., rm. 286,

Rockville, MD 20855.

14 Mailing address: 9200 Corporate Blvd.,

Rockville, MD 20850.

15Mailing address: 1350 Piccard Dr., Rockville,

MD 20850.

16Mailing address: 2098 Gaither Rd., Oak Grove

Corporate Park, Rockville, MD 20850.

17Mailing address: 9200 Corporate Blvd.,

Rockville, MD 20850.

18Mailing address: 2098 Gaither Rd., Rockville,

MD 20850.

19Mailing address: 12720 Twinbrook Pkwy.,

Bldg. 1, Rockville, MD 20857.

20Mailing address: 1350 Piccard Dr., Rockville,

MD 20850.

21Mailing address: 200 C St. SW., Washington,

DC 20204.

Equal Employment Opportunity Staff.

Regulatory Policy Staff.

Office of Management

Administrative Staff.

Division of Planning, Evaluation, and

Resource Management.

Division of Management Services.

Division of Information Systems Design.

Division of Database Management.

Office of Training and Communications

Freedom of Information Staff.

Division of Training and Development.

Division of Communications

Management.

Division of the Medical Library.

Office of Compliance

Division of Labeling and

Nonprescription Drug Compliance.

Division of Prescription Drug

Compliance and Surveillance.

Division of Manufacturing and Product

Quality.

Division of Scientific Investigations.

Office of Pharmaceutical Science

Office of the Director

Product Quality Support Staff.

Operations Staff.

Office of New Drug Chemistry

Division of New Drug Chemistry I.

Division of New Drug Chemistry II.

Division of New Drug Chemistry III.

Office of Generic Drugs13

Division of Chemistry I.

Division of Chemistry II.

Division of Bioequivalence.

Division of Labeling and Program

Support.

Office of Clinical Pharmacology and

Biopharmaceutics

Division of Pharmaceutical Evaluation I.

Division of Pharmaceutical Evaluation

II.

Division of Pharmaceutical Evaluation

III.

Office of Testing and Research

Laboratory of Clinical Pharmacology.

Regulatory Research and Analysis Staff.

Division of Product Quality Research.

Division of Applied Pharmacology

Research.

Division of Testing and Applied

Analytical Development.

Office of Review Management

Office of the Director

Advisors and Consultants Staff.

Office of Drug Evaluation I

Division of Neuropharmacological Drug

Products.

Division of Oncology Drug Products.

Division of Cardio-Renal Drug Products.

Division of Drug Marketing, Advertising

and Communication.

Office of Drug Evaluation II

Division of Metabolic and Endocrine

Drug Products.

Division of Pulmonary Drug Products.

Office of Drug Evaluation III

Division of Gastrointestinal and

Coagulation Drug Products.

Division of Anesthetic, Critical Care,

and Addiction Drug Products.

Division of Medical Imaging and

Radiopharmaceutical Drug Products.

Office of Drug Evaluation IV

Division of Anti-Infective Drug

Products.

Division of Anti-Viral Drug Products.

Office of Drug Evaluation V

Division of Anti-Inflammatory,

Analgesic, and Ophthalmologic Drug

Products.

Division of Dermatologic and Dental

Drug Products.

Division of Over-The-Counter Drug

Products.

Office of Epidemiology and Biostatistics

Quantitative Methods and Research

Staff.

Division of Pharmacovigilance and

Epidemiology.

Division of Biometrics I.

Division of Biometrics II.

Division of Biometrics III.

Division of Biometrics IV.

Center for Devices and Radiological

Health.14

Office of the Center Director

Equal Employment Opportunity Staff.

Office of Systems and Management

Integrity, Committee and Conference

Management Staff.

Division of Management Operations.

Division of Information Dissemination.

Division of Information Technology

Management.

Division of Planning, Analysis and

Finance

Office of Health and Industry

Programs15

Division of Device User Programs and

Systems Analysis.

Division of Small Manufacturers

Assistance.

Division of Mammography Quality and

Radiation Programs.

Division of Communication Media.

Program Operations Staff.

Office of Compliance16

Promotion and Advertising Policy Staff.

Division of Program Operations.

Division of Bioresearch Monitoring.

Division of Enforcement I.

Division of Enforcement II.

Division of Enforcement III.

Office of Device Evaluation17

Program Operations Staff.

Program Management Staff.

Division of Cardiovascular, Respiratory,

and Neurological Devices.

Division of Reproductive, Abdominal,

Ear, Nose, and Throat, and Radiological

Devices.

Division of General and Restorative

Devices.

Division of Clinical Laboratory

Devices.18

Division of Ophthalmic Devices.

Division of Dental, Infection Control,

and General Hospital Devices.

Office of Science and Technology19

Division of Mechanics and Materials

Science.

Division of Life Sciences.

Division of Physical Sciences.

Division of Electronics and Computer

Sciences.

Division of Management, Information,

and Support Services.

Office of Surveillance and Biometrics20

Division of Biostatistics.

Division of Postmarket Surveillance.

Division of Surveillance Systems.

Office of Health and Industry Programs

Division of Device User Programs and

Systems Analysis.

Division of Small Manufacturers

Assistance.

Division of Mammography Quality and

Radiation Programs.

Division of Communication Media.

Center for Food Safety and Applied

Nutrition.21

Office of the Center Director

Equal Employment Opportunity Staff.

Office of Beltsville Technical Operations

Office of Policy, Planning and Strategic

Initiatives

Executive Operations Staff.

Office of Programs

Beltsville Technical Operations Staff.

Office of Cosmetics and Colors

Division of Programs and Enforcement

Policy.

Division of Science and Applied

Technology.

Office of Food Labeling

Division of Programs and Enforcement

Policy.

Division of Technical Evaluation.

Division of Science and Applied

Technology.

Office of Premarket Approval

Division of Product Policy.

Division of Petition Control.

Division of Health Effects Evaluation.

Division of Molecular Biological

Research and Evaluation.

Division of Product Manufacture and

Use.
13824 Federal Register / Vol. 62, No. 56 / Monday, March 24, 1997 / Rules and Regulations

22Mailing address: 7500 Standish Pl., MPN–2,

Rockville MD 20855.

Office of Plant and Dairy Foods and

Beverages

Division of Programs and Enforcement

Policy.

Division of Virulence Assessment.

Division of Pesticides and Industrial

Chemicals.

Division of Natural Products.

Division of Food Processing and

Packaging.

Office of Seafood

Division of Special Programs.

Division of Programs and Enforcement

Policy.

Division of Science and Applied

Technology.

Office of Special Nutritionals

Clinical Research and Review Staff.

Division of Programs and Enforcement

Policy.

Division of Science and Applied

Technology.

Office of Special Research Skills

Division of Toxicology Research.

Division of Microbiological Studies.

Office of Systems and Support

Quality Assurance Staff.

Office of Constituent Operations

Consumer Education Staff.

Legislative Activities Staff.

Industry Activities Staff.

International Activities Staff.

Office of Field Programs

Division of Enforcement.

Division of HACCP Programs.

Division of Cooperative Programs.

Division of Field Program Planning and

Evaluation.

Office of Management Systems

Safety Management Staff.

Division of Information Resources

Management.

Division of Planning and Resources

Management.

Office of Scientific Analysis and

Support

Division of Mathematics.

Division of General Scientific Support.

Division of Market Studies.

Center for Veterinary Medicine.22

Office of the Center Director

Office of Management and

Communications

Administrative Staff.

Communications Staff.

Program Planning and Evaluation Staff.

Information Resources Management

Staff.

Office of Surveillance and Compliance

Division of Compliance.

Division of Animal Feeds.

Division of Epidemiology and

Surveillance.

Office of New Animal Drug Evaluation

Division of Biometrics and Production

Drugs.

Division of Manufacturing

Technologies.

Division of Therapeutic Drugs for Food

Animals.

Division of Therapeutic Drugs for NonFood Animals.

Division of Human Food Safety.

Office of Research

Administrative Staff.

Division of Residue Chemistry.

Division of Animal Research.

§ 5.105 [Redesignated as § 5.205]

3. Section 5.105 is redesignated as

§ 5.205.

4. Section 5.110 is redesignated as

§ 5.210 and revised to read as follows:

§ 5.210 FDA Public Information Offices.

(a) Dockets Management Branch

(HFA–305). The Dockets Management

Branch Public Room is located in rm. 1–

23, 12420 Parklawn Dr., Rockville, MD

20857. Telephone: 301–443–1753.

(b) Freedom of Information Staff

(HFI–35). The Freedom of Information

Public Room is located in rm. 12A–30,

Parklawn Bldg., 5600 Fishers Lane,

Rockville, MD 20857. Telephone: 301–

443–6310.

(c) Press Relations Staff (HFI–40). The

Press Offices are located in rm. 15–05,

Parklawn Bldg., 5600 Fisher Lane,

Rockville, MD 20857. Telephone: 301–

443–3285; and in rm. 3807, FB–8, 200

C St. SW., Washington, DC 20204.

Telephone 202–205–4144.

5. Section 5.115 is redesignated as

§ 5.215 and revised to read as follows:

§ 5.215 Field structure.

NORTHEAST REGION

Regional Field Office: 850 Third Ave.,

Brooklyn, NY 11232.

Northeast Regional Laboratory: 850

Third Ave., Brooklyn , NY 11232–1593.

New York District Office: 850 Third

Ave., Brooklyn, NY 11232–1593.

New England District Office: One

Montvale Ave., Stoneham, MA 02180.

Buffalo District Office: 599 Delaware

Ave., Buffalo, NY 14202.

MID–ATLANTIC REGION

Regional Field Office: 900 U.S.

Customhouse, Second and Chestnut

Sts., rm. 900, Philadelphia, PA 19106.

Philadelphia District Office: 900 U.S.

Customhouse, Second and Chestnut

Sts., rm. 900, Philadelphia, PA 19106.

Baltimore District Office: 900 Madison

Ave., Baltimore, MD 21201–2199.

Cincinnati District Office: 1141 Central

Pkwy., Cincinnati, OH 45202–1097.

New Jersey District Office: Waterview

Corporate Center, 10 Waterview Blvd.,

3d Floor, Parsippany, NJ 07054.

SOUTHEAST REGION

Regional Field Office: 60 Eighth St. NE.,

Atlanta, GA 30309.

Southeast Regional Laboratory: 60

Eighth St. NE., Atlanta, GA 30309.

Atlanta District Office: 60 Eighth St.

NE., Atlanta, GA 30309.

Nashville District Office: 297 Plus Park

Blvd., Nashville, TN 37217.

New Orleans District Office: 4298

Elysian Fields Ave., New Orleans, LA

70122.

Florida District Office: 7200 Lake

Ellenor Dr., suite 120, Orlando, FL

32809.

San Juan District Office: 466 Fernandez

Juncos Ave., San Juan, PR 00901–3223.

MIDWEST REGION

Regional Field Office: 20 North

Michigan Ave., rm. 510, Chicago, IL

60602.

Chicago District Office: 300 South

Riverside Plaza, suite 550, South

Chicago, IL 60606.

Detroit District Office: 1560 East

Jefferson Ave., Detroit, MI 48207–3179.

Minneapolis District Office: 240

Hennepin Ave., Minneapolis, MN

55401–1912.

SOUTHWEST REGION

Regional Field Office: 7920 Elmbrook

Dr., Dallas, TX 75247–4982.

Dallas District Office: 3310 Live Oak St.,

Dallas, TX 75204.

Denver District Office: Bldg. 20, Denver

Federal Center, Sixth and Kipling Sts.,

P.O. Box 25087, Denver, CO 80225–

0087.

Kansas City District Office: 11630 West

80th St., Lenexa, KS 66214.

St. Louis Branch: 12 Sunnen Dr., St.

Louis, MO 63143.

PACIFIC REGION

Regional Field Office: 1301 Clay St.,

suite 1180–N, Oakland, CA 94612–

5217.San Francisco District Office: 1431

Harbor Bay Parkway, Alameda, CA

94502–7070.

Los Angeles District Office: 19900

MacArthur Blvd., suite 300, Irvine, CA

92715–2445.

Seattle District Office: 22201 23d Dr.

SE., Bothell, WA 98021–4421.

Dated: March 17, 1997.

William K. Hubbard,

Associate Commissioner for Policy

Coordination.

[FR Doc. 97–7278 Filed 3–21–97; 8:45 am]

BILLING CODE 4160–01–F